Fazlic Diego López, García Samuel Abrante, Gerard Micaela, Izquierdo Edduin Martín, Bethencourt Alejandro Alonso, Vannini Luca, García Celestino Hernández, Heras Manuel Macía
Cardiology Department, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Tenerife, Spain.
Nephrology Department, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Tenerife, Spain.
Clin Kidney J. 2024 Jul 29;17(8):sfae233. doi: 10.1093/ckj/sfae233. eCollection 2024 Aug.
Cardiac amyloidosis is a cardiomyopathy resulting from the extracellular deposition of proteins such as transthyretin (TTR). We present the case of a 72-year-old male with hereditary cardiac amyloidosis. After confirming the diagnosis, tafamidis, a TTR stabilizer, was administered. Remarkably, tafamidis, when coupled with peritoneal dialysis for chronic kidney disease, maintained stability in both cardiac and renal functions. Previous studies have demonstrated the efficacy of tafamidis in reducing all-cause mortality and cardiovascular hospitalizations, although its use in severe renal failure lacks specific evaluation. This case suggests a potential application of tafamidis in moderate-severe kidney disease, emphasizing the need for further research in this population.
心脏淀粉样变性是一种由诸如转甲状腺素蛋白（TTR）等蛋白质在细胞外沉积导致的心肌病。我们报告一例72岁患有遗传性心脏淀粉样变性的男性病例。确诊后，给予TTR稳定剂塔非酰胺进行治疗。值得注意的是，塔非酰胺与慢性肾病的腹膜透析联合使用时，心脏和肾功能均保持稳定。既往研究已证明塔非酰胺在降低全因死亡率和心血管住院率方面的疗效，尽管其在严重肾衰竭中的应用缺乏具体评估。该病例提示塔非酰胺在中重度肾病中具有潜在应用价值，强调了在该人群中进一步研究的必要性。
